kras mutation and glutathion KRAS-targeted therapies in cancer: novel approaches overcoming resistance Overcoming resistance to drugs targeting
Overcoming resistance to drugs targeting KRASG12C mutation Uncovering new therapeutic targets for a common KRAS mutation behind cancer KRAS Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions PMC KRAS G12V mutation selective requirement for ACSS2 in colorectal adenoma formation: Cell Reports KRAS OriGene Technologies Inc.
Pay in 4 interest-free payments of $6.69 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10




